Are you Dr. Petrich?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 52 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
676 N. St Clair, Suite 2100
Chicago, IL 60611Phone+1 312-695-6180Fax+1 312-695-4770- Is this information wrong?
Summary
- Dr. Adam Petrich, MD is an oncologist in Chicago, Illinois. He is currently licensed to practice medicine in Illinois. He is an Assistant Professor in Medicine-Hematology/Oncology at Northwestern University Medical School.
Education & Training
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Fellowship, Hematology and Medical Oncology, 2008 - 2011
University of Wisconsin Hospitals and ClinicsResidency, Internal Medicine, 2005 - 2008
University of Illinois College of MedicineClass of 2005
Certifications & Licensure
IL State Medical License 2011 - 2017
Clinical Trials
- Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma Start of enrollment: 2010 Apr 15
- Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers Start of enrollment: 2012 Feb 27
- Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma Start of enrollment: 2015 Jun 11
- Join now to see all
Publications & Presentations
PubMed
- A phase 1-2 trial of DA-EPOCH-R plus ixazomib for MYC-aberrant lymphoid malignancies: the DACIPHOR regimen.Karmali, R., Reem Karmali, Carlos Galvez, Mehdi Hamadani, Leo Gordon, Jane Winter, Shuo Ma, Valerie Nelson, Timothy S Fenske, Nirav N Shah, Deepa Jagadeesh, Andreas Kl...> ;Blood Advances. 2024 Apr 9
- 7 citationsEftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study.Patricia LoRusso, Mark J Ratain, Toshihiko Doi, Drew W Rasco, Maja J A de Jonge, Victor Moreno, Benedito A Carneiro, Lot A Devriese, Adam Petrich, Dimple Modi, Susan M...> ;Investigational New Drugs. 2022 Aug 1
- 12 citationsA phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV + lymphomas.William Pearse, Adam M. Petrich, Leo I. Gordon, Reem Karmali, Jane N. Winter, Shuo Ma, Jason B. Kaplan, Amir Behdad, Andreas K. Klein, Borko Jovanovic, Irene Helenowsk...> ;Leukemia & Lymphoma. 2021 Aug 2
- Join now to see all
